South Korea's first homegrown obesity drug won approval, and Hanmi set its price to take on Wegovy and Mounjaro in the local market.
Recap by typeshit. Full story at KED Global.
An explainer on talking to a provider about whether Wegovy fits you, plus a reminder that insurance may not pay for it.
Khunti shares real-world data on over a million UK adults using telehealth for obesity care, where 90% started on tirzepatide before a major price hike changed prescribing.
Polskie Radio reports a Wegovy price cut in China, coming soon after the drug's approval there. Tap through for the details.
Novo Nordisk is cutting what Wegovy costs in China, Polskie Radio reports. Tap through for the size of the cut and when it takes effect.
The interim access policy went to OMB review, and Hims & Hers shares rose nearly 6%. Leerink sizes the possible market at $2.2B a year.
A Facebook newsletter looks at how GLP-1 research is moving past diabetes and obesity into cardiovascular and kidney care.
Loading…